People want drug industry oversight

Share this article:
US adults want information on and oversight of the drug industry, according to a recent Harris Poll. Poll officials said 71% of adults surveyed believe it is very important or highly important that marketed drugs remain under close review by the FDA and drug companies. Only 9% of respondents said such review is only somewhat or not very important.

The researchers said many Americans are demonstrating consumerism by seeking information on drug safety, with 41% of those surveyed saying they always or often seek information on drug safety for themselves or family members.

Another 35% said they sometimes seek drug safety information, while only 24% said they rarely or never look for safety information.

There were age differences in the responses, with those who are older more likely to be concerned about drug safety.

“The public's desire for drug safety information and their belief that drugs should remain under continued review by FDA and drug companies indicates that Americans may have concerns regarding the full safety profile of all drugs,” the pollsters said. “These questions on safety may be negatively affecting their impressions of the industry…Ultimately, the findings continue to highlight the need for drug companies to build and maintain consumer confidence as a key component of their overall corporate reputation.”

Share this article:

Email Newsletters

More in News

House bill would speed approval once EU OKs same product

House bill would speed approval once EU OKs ...

The Speeding Access to Already Approved Pharmaceuticals Act of 2014 would require FDA to expedite the review of pharmaceuticals that are already approved by the European Union

Rep access continues to shrink

Rep access continues to shrink

Sales reps are experiencing even more limited physician access, according to a report by Chicago consultancy ZS Associates.

Allergan touts reorg, plans to lay off 13% of workforce

Allergan touts reorg, plans to lay off 13% ...

Allergan's second-quarter earnings, and a new round of cuts, are now part of the Botox maker's record as it seeks to remain independent.